Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571) [1]

Leukemia and Lymphoma

Volumn 44, Issue 7, 2003, Pages 1251-1253

  Schittenhelm, M ^a   Aichele, O ^a   Krober S M ^b   Brummendorf T ^a   Kanz, L ^a   Denzlinger, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

AML; c Kit; CD117; Glivec; Imatinib; STI 571

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERLEUKIN 2; MELPHALAN; MITOXANTRONE; STEM CELL FACTOR; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CELL; CANCER RECURRENCE; CASE REPORT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LETTER; LEUKEMIA REMISSION; MEDICAL DECISION MAKING; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 0037648683     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000077034     Document Type: Letter

References (6)

1. Savage, D.G. and Antman, K.H. (2002) "Imatinib mesylate - a new oral targeted therapy", N. Engl. J. Med. 346, 683-693.
2. Denzlinger, C., Bowen, D., Benz, D., Gelly, K., Brugger, W. and Kanz, L. (2000) "Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukemia", Br. J. Haematol. 108, 93-95.
3. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, L.M., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J.M., Bernstein, I.D. and Appelbaum, F.R. (2001) "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", J. Clin. Oncol. 19, 3244-3254.
4. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Tos, A.G. and Mandelli, F. (1994) "Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia", Blood 84, 2158-2163.
5. Radsak, M.P., Salih, H.R., Sökler, M., Kanz, L. and Denzlinger, C. (2002) "Sustained complete remission of recurrent acute myeloid leukemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenace", Leukemia 16, 1870-1871.
6. Heinrich, M.C., Griffith, J., Druker, B., Wait, C.L., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor", Blood 96, 925-932.